SEIA
ABCL icon

Signature Estate & Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Signature Estate & Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,668
Closed -$124K – 670
2026
Q1 		$124K Hold
35,668
– – ﹤0.01% 637
2025
Q4 		$122K Sell
35,668
-3,000
-8% -$13.4K ﹤0.01% 598
2025
Q3 		$195K Sell
38,668
-1,000
-3% -$4.41K ﹤0.01% 582
2025
Q2 		$136K Hold
39,668
– – ﹤0.01% 565
2025
Q1 		$88.5K Hold
39,668
– – ﹤0.01% 542
2024
Q4 		$116K Hold
39,668
– – ﹤0.01% 527
2024
Q3 		$103K Hold
39,668
– – ﹤0.01% 515
2024
Q2 		$117K Buy
+39,668
New +$150K ﹤0.01% 496

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Signature Estate & Investment Advisors's ABCL Position: Q2 2026 in Review

Signature Estate & Investment Advisors sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 35,668 shares — an estimated $124K sold.

Signature Estate & Investment Advisors first reported a position in ABCL in Q2 2024 and held it in 8 quarters. The position peaked at $195K in Q3 2025. 59 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Signature Estate & Investment Advisors reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • Signature Estate & Investment Advisors sold 35,668 AbCellera Biologics shares in Q2 2026, an estimated $124K.
  • Signature Estate & Investment Advisors first reported a position in AbCellera Biologics in Q2 2024 and held it in 8 quarters.
  • Signature Estate & Investment Advisors's AbCellera Biologics position peaked at $195K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.